Zerofos DS Tablet

Zerofos DS Tablet contains calcium acetate, a phosphate-binding agent commonly prescribed for patients with advanced chronic kidney disease, especially those on haemodialysis or peritoneal dialysis. In healthy individuals, the kidneys remove excess phosphate from the blood, but impaired kidney function leads to phosphate retention.

Calcium acetate works within the gastrointestinal tract by binding phosphate from food to form insoluble calcium phosphate complexes. These complexes are then eliminated through the stool, reducing phosphate absorption and lowering blood phosphate levels.

By controlling hyperphosphataemia, calcium acetate helps prevent complications such as bone pain, bone fractures, vascular calcification, and secondary hyperparathyroidism. Maintaining appropriate phosphate levels is essential for long-term bone strength and cardiovascular health in patients with kidney disease.

The medicine is taken with meals to maximise phosphate binding from food. Treatment response depends on dietary phosphate intake, adherence to dosing with meals, and regular monitoring of blood phosphate and calcium levels. When used as prescribed, Zerofos DS Tablet is an effective and well-established therapy for phosphate control in chronic kidney disease.

Hyperphosphataemia in Chronic Kidney Disease

Used to reduce high blood phosphate levels in patients with severe kidney impairment.

Dialysis Patients

Commonly prescribed for patients on haemodialysis or peritoneal dialysis to control phosphate balance.

Prevention of Bone Disorders

Helps reduce the risk of renal bone disease caused by prolonged phosphate imbalance.

Reduction of Vascular Calcification Risk

Supports long-term cardiovascular health by limiting phosphate-related calcification.

Effective Phosphate Binding

Binds dietary phosphate in the gastrointestinal tract and significantly reduces its absorption into the bloodstream.

Improved Phosphate Control

Helps maintain target blood phosphate levels when taken consistently with meals and dietary guidance.

Supports Bone Health

Reduces the risk of bone pain, bone weakening, and fractures associated with chronic kidney disease–related mineral imbalance.

Reduces Secondary Hyperparathyroidism Risk

By lowering phosphate levels, it helps reduce overstimulation of the parathyroid glands over time.

Cardiovascular Protection

Limits phosphate-related vascular and soft tissue calcification, supporting long-term heart and blood vessel health.

Well-Established Renal Therapy: Widely used and supported by clinical evidence in patients with advanced chronic kidney disease.

Meal-Time Targeted Action: Works directly with dietary phosphate intake, making it effective when taken alongside meals as prescribed.

Zerofos DS Tablet is generally well tolerated when taken as prescribed, though side effects may occur in some patients.

Common Side Effects

• Constipation

• Nausea or vomiting

• Abdominal discomfort

• Loss of appetite

Uncommon Side Effects

• Diarrhoea

• Gas or bloating

• Mild stomach pain

Serious Side Effects (Require Immediate Medical Attention)

• Hypercalcaemia: Weakness, confusion, vomiting, excessive thirst, or frequent urination.

• Severe Constipation or Bowel Obstruction: Persistent abdominal pain or inability to pass stools.

• Soft Tissue Calcification: Rare but serious complications with prolonged high calcium levels.

Zerofos DS Tablet should be taken exactly as prescribed by the doctor, usually with meals to ensure effective phosphate binding. Tablets should be swallowed whole with water unless otherwise directed.

Do not take the medicine on an empty stomach, as it works best when taken with food. Regular blood tests are necessary to monitor phosphate and calcium levels and adjust the dose if needed.

The mechanism of Zerofos DS Tablet is based on its ability to bind dietary phosphate within the gastrointestinal tract before it can be absorbed into the bloodstream. Calcium acetate dissociates in the stomach to release calcium ions, which readily combine with phosphate present in food.

This binding forms insoluble calcium phosphate complexes that cannot pass through the intestinal wall. These complexes are then eliminated from the body through the stool, effectively reducing the amount of phosphate absorbed into the blood.

By lowering phosphate absorption, calcium acetate helps reduce elevated blood phosphate levels in patients with impaired kidney function. This supports better regulation of calcium–phosphate balance, helping prevent bone disease, vascular calcification, and other complications associated with chronic kidney disease when used consistently with meals and regular monitoring.

• Strict Meal-Time Use: Take the medicine with every main meal or snack containing phosphate to ensure effective binding of dietary phosphate.

• Dietary Adherence: Follow a low-phosphate diet as advised by a renal dietitian, as medication alone may not control phosphate levels adequately.

• Regular Blood Monitoring: Periodic monitoring of serum phosphate, calcium, and parathyroid hormone levels is essential to guide dose adjustments.

• Avoid Extra Calcium Intake: Do not take additional calcium supplements or fortified products unless specifically prescribed, as this may increase the risk of high calcium levels.

• Constipation Management: Adequate fluid intake and dietary fibre may help reduce constipation, a common side effect of calcium-based binders.

• Consistent Use: Skipping doses or taking the medicine without food may reduce phosphate control and increase long-term complication risk.

• High-Phosphate Foods (High): Excessive intake of dairy products, processed foods, colas, and packaged snacks can reduce the effectiveness of phosphate control.

• Iron-Rich Foods (Moderate): Calcium can interfere with iron absorption if taken together, so spacing intake may be necessary.

• Oxalate-Rich Foods (Low): Foods such as spinach or nuts may bind calcium and slightly affect phosphate-binding efficiency.

• Iron Supplements (Moderate): Calcium reduces iron absorption, so doses should be separated by several hours.

• Tetracycline and Fluoroquinolone Antibiotics (Moderate): Calcium can significantly reduce antibiotic absorption if taken together.

• Levothyroxine (Moderate): Calcium interferes with thyroid hormone absorption and should be taken at least four hours apart.

• Bisphosphonates (Moderate): Concurrent intake may reduce absorption, requiring separation of dosing times.

• Vitamin D Analogues (Moderate): Combined use may increase the risk of elevated calcium levels and requires close monitoring.

• Hypercalcaemia (High): Use may worsen elevated calcium levels and should be avoided or closely monitored in affected patients.

• Severe Constipation or Bowel Disorders (Moderate): The medicine may aggravate gastrointestinal symptoms in patients with reduced bowel motility.

• Parathyroid Disorders (Moderate): Altered calcium–phosphate balance requires careful monitoring to prevent bone and mineral complications.

• History of Kidney Stones (Moderate): Increased calcium load may raise the risk of stone formation in susceptible individuals.

If you miss a dose, take it with your next meal. Do not take a double dose to make up for the missed one. Skipping doses may reduce phosphate control, so consistent use with meals is important.